I wouldn't be surprised if that's actually an underestimate, because this saga has had a knock on effect on decongestant formulations sold outside the US as well. I don't know exactly why this has happened but my guess is it may be due to economies of scale in manufacturing or licencing overheads.

It's hard to find a pharmacy which even sells pseudoephedrine based decongestant if you're in the UK, for example.